-
1 Comment
Techno Medica Co., Ltd is currently in a long term downtrend where the price is trading 0.7% below its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Techno Medica Co., Ltd's total revenue sank by 3.2% to $2B since the same quarter in the previous year.
Its net income has increased by 51.4% to $269M since the same quarter in the previous year.
Based on the above factors, Techno Medica Co., Ltd gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Devices |
| Exchange | TSE |
| CurrencyCode | JPY |
| ISIN | JP3545110003 |
| Dividend Yield | 7.6% |
|---|---|
| PE Ratio | 11.28 |
| Target Price | None |
| Beta | 0.04 |
| Market Cap | 12B |
Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers automated tube selecting and labeling systems, RFID specimen management, inspection reception systems, reception and collation systems, automated urine aliquot and labeling systems, pre-analytical instruments, and blood and urine collection support, as well as blood gas, electrolytes, erythrocyte sedimentation rates, and ion selective electrode-certificated serums. It also provides consumables and after sales services. Techno Medica Co., Ltd. was incorporated in 1987 and is headquartered in Yokohama, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 6678.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
